Company intelligence / Profile preview

Flamel Technologies

Lyon, France

Ownership: Private
Employees: ~150
Development stage: Other

Overview

Flamel developed hospital and primary care drugs using proprietary drug delivery platforms, with marketed products such as Bloxiverz (neostigmine methylsulfate injection) and Vazculep (phenylephrine hydrochloride injection), and an internal pipeline that included Phase 2 trials for long-acting interferon alpha and development programs for extended-release sodium oxybate

Therapeutic areas: EndocrinologyCardiovascularNeurologyInfectious DiseasesRare Diseases
Modalities: Small moleculeBiologicPeptidesInjectable drug deliveryExtended/controlled-release drug delivery
Industry: Biotech

Partnerships

GlaxoSmithKline (Coreg CR/carvedilol phosphate)Merck Serono (long-acting interferon beta-1a)Baxter (various drug delivery collaborations)Elan Pharma (LiquiTime US OTC market)

Beyond the preview

Go deeper on Flamel Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Flamel Technologies.

Explore the full profile